ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,399Medicare Part D Prescriptions Filled, Including Refills

Rank: 448 out of 1121

$857K Total Retail Price of All Prescriptions

Rank: 118 out of 1121

330 Patients Receiving at Least One Drug in Part D
64%Patients 65 Years and Older
64% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Tennessee
Lower avg

Schedule Two
Controlled Substances

19% of this provider’s 330 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

11% of this provider’s 330 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 5,061 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

37% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$102 was the average price of a prescription from this provider, compared to $55 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Tennessee
AMLODIPINE BESYLATE 340 238 1 5
CRESTOR 306 203 2 28
MORPHINE SULFATE ER 273 23 S2 3 87
SIMVASTATIN 227 161 4 1
CHLORTHALIDONE 209 150 5 149
METFORMIN HCL 201 124 6 8
GABAPENTIN 200 76 7 13
HYDROCODONE-ACETAMINOPHEN 185 70 S3 8 3
LEVOTHYROXINE SODIUM 184 123 9 2
LISINOPRIL 181 111 10 4
BYSTOLIC 172 93 11 121
ATENOLOL 171 107 12 16
OMEPRAZOLE 155 83 13 6
ZOLPIDEM TARTRATE 147 62 14 19
LISINOPRIL-HYDROCHLOROTHIAZIDE 136 86 15 31
CYMBALTA 134 79 16 50
AMLODIPINE BESYLATE-BENAZEPRIL 132 89 17 65
MORPHINE SULFATE 131 13 S2 18 238
OPANA ER 120 38 S2 19 213
WARFARIN SODIUM 115 82 20 11
CARVEDILOL 108 57 21 20
METOPROLOL SUCCINATE 103 81 22 23
HYDROCHLOROTHIAZIDE 99 74 23 10
BENAZEPRIL HCL 92 63 24 41
POTASSIUM CHLORIDE 90 73 25 12
FLUTICASONE PROPIONATE 88 46 26 36
ALENDRONATE SODIUM 85 78 27 37
GLIMEPIRIDE 81 60 28 34
SERTRALINE HCL 80 61 29 21
SPIRONOLACTONE 78 65 30 54
PROMETHAZINE HCL 74 0 R 31 67
NEXIUM 66 0 32 24
LYRICA 65 14 33 76
ATORVASTATIN CALCIUM 65 49 33 15
TAMSULOSIN HCL 64 61 35 32
ALLOPURINOL 64 53 35 30
PROAIR HFA 61 20 37 48
SINGULAIR 60 42 38 78
LEVEMIR FLEXPEN 58 44 39 222
FENTANYL 57 36 S2 40 100
CLOPIDOGREL 57 47 40 27
TORSEMIDE 55 46 42 155
ADVAIR DISKUS 53 29 43 64
NATEGLINIDE 52 50 44 246
METOPROLOL TARTRATE 52 47 44 9
ACTOS 50 42 46 133
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 10, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.